Appendix

mRNA mediates passive vaccination against infectious agents, toxins and tumors

Moritz Thran, Jean Mukherjee, Marion Pönisch, Katja Fiedler, Andreas Thess, Barbara L. Mui, Michael J. Hope, Ying K. Tam, Nigel Horscroft, Regina Heidenreich, Mariola Fotin-Mleczek, Charles B. Shoemaker, Thomas Schlake

This appendix includes 10 figures and 4 tables

		Page
Table of Contents		1
Appendix Figure S1.	Solitary heavy chain molecules are retained in the cytoplasm.	2
Appendix Figure S2.	Titration of the molar ratio of heavy and light chain-encoding mRNAs.	3
Appendix Figure S3.	Various mAbs can be expressed by exogenous mRNA in vitro.	4
Appendix Figure S4.	Kinetics of mRNA-LNP expression in vitro and in vivo.	5
Appendix Figure S5.	Cartoon illustration of the assay for measuring antigen-binding	6
	by mRNA-encoded mAbs.	
Appendix Figure S6.	Inhibition of HIV cell entry determined by a Magi R5-Tropic	7
	Antiviral Assay.	
Appendix Figure S7.	In vivo expression analyses of anti-influenza B mAb and VNAs.	8
Appendix Figure S8.	Correlation of IgG titers and ADA responses.	9
Appendix Figure S9.	Histopathological analysis of liver sections after mRNA-LNP treatment.	10
Appendix Figure S10.	Protection of mice against BoNT/A challenge by mRNA-LNP	11
	administered at various times post intoxication.	
Appendix Table S1.	Analysis of cytokine induction following mRNA-LNP administration.	12
Appendix Table S2.	Supporting information Fig. 4b.	13
Appendix Table S3.	Supporting information Fig. 4d.	14
Appendix Table S4.	Supporting information Fig. 4e.	15-16



Appendix Figure S1. Solitary heavy chain molecules are retained in the cytoplasm.

- A, C, E mRNAs encoding heavy chain (HC) and light chain (LC), respectively, were transfected in different combinations into BHK (A and C) or HepG2 (E) cells and expression profiles were analyzed from lysates and supernatants by western blot. Equal amounts of three replicates were pooled and loaded on denaturing SDS-PAGE followed by western blot analysis.
- B, D, F Individual supernatants (triplicates) that were pooled for (A), (Ć) and (E) were analyzed by IgG-specific ELISA. For mock co-transfections (indicated as (-)), an mRNA encoding eGFP was used.

Data information: Data in B, D and F are expressed as means ± SD.



Appendix Figure S2. Titration of the molar ratio of heavy and light chain-encoding mRNAs.

A, B, C, D Quantification of mAb levels from BHK cell supernatants by IgG-specific ELISA. BHK cells were transfected with various ratios of heavy and light chain-encoding mRNAs giving rise to mAbs against influenza B (A), rabies (B), HIV (C), or human CD20 (D). Measurements were conducted in quadruplicate.

Data information: Data are expressed as means ± SD.



Appendix Figure S3. Various antibodies can be expressed by exogenous mRNA in vitro.

 A, C, E, G
 mRNAs encoding distinct antibodies were transfected into BHK cells and expression was analyzed in lysates and supernatants by denaturing SDS-PAGE followed by western blot analysis. Equal amounts of three replicates were pooled for gel electrophoresis.
 B, D, F, H
 Quantification of titers from supernatants of BHK cells by IgG- (B, D, F) or antigen-specific ELISA (H). Titers were determined in biological triplicates.

Data information: Data in B, D, F and H are expressed as means \pm SD.



Appendix Figure S4. Kinetics of mRNA-LNP expression in vitro and in vivo.

- А
- Primary mouse hepatocytes were transfected with mRNA-LNP encoding anti-rabies mAb. Expression of mAb at various times was determined in biological duplicates by IgG-specific ELISA. Mice received 30 µg of mRNA-LNP encoding MfEpo. В
 - Expression of MfEpo at various times was determined in biological duplicates by ELISA.

Data information: Data are expressed as means ± SD.



HeLa cells transfected with mRNA-encoded antigens (or CD20-positive Raji cells)

Incubation with cell supernatant containing mRNA-encoded mAbs

Incubation with biotinylated anti-human IgG antibodies

Incubation with Streptavidin-PE & FACS detection

Appendix Figure S5. Cartoon illustration of the assay for measuring antigen-binding by mRNA-encoded mAbs.

If no natural target cells were available, HeLa cells were transfected to express the cognate antigen of the mAb of interest. Following incubation with mAb-containing supernatants from BHK cells, Hela or Raji cells were further incubated with anti-human IgG specific biotinylated antibody and finally incubated with streptavidin-coupled phycoerythrin (PE). Binding specificity correlates with PE intensity and can be assessed by semi-quantitative FACS analysis.



Appendix Figure S6. Inhibition of HIV cell entry determined by a Magi R5-Tropic Antiviral Assay.

A, B, C, D mRNA encoding VRC01 was transfected into BHK cells in triplicates. BHK supernatants were pooled and added to MAGI-R5 cells before Ba-L strain of HIV-1 was then added to the cells. Virus entry was measured via chemiluminescence. Depicted is the ratio of chemiluminescence compared to a virus control (VC) which represents infected cells in the absence of any test compound. Cell control (CC) measurements were carried out to analyze cell viability at different dilutions of medium in the absence of virus. A serial dilution of supernatants of untransfected cells (A), cells transfected with RNA encoding VRC01 (B), recombinant VRC01 (C) and the TAK779 inhibitor (D) was carried out and the virus entry was measured. Dotted lines indicate an inhibition of 50% (IC₅₀) and of 90% (IC₉₀) compared to virus control.

Data information: Data are expressed as means ± SD.



Appendix Figure S7. In vivo expression analyses of anti-influenza B mAb and VNAs.

- A Quantification of mAb titers by IgG-specific ELISA of sera obtained 24 hours after a single intravenous injection of increasing doses of mRNA-LNP encoding anti-influenza B mAb into mice.
 B Quantification of VNA titers by antigen-specific ELISA at various times after a single intravenous injection
- 6 Guantification of VNA iters by antigen-specific ELISA at various times after a single intravenous injection of 40 µg of mRNA-LNP encoding VNA-Stx2. For each time point, a different cohort of mice was used.
- C, D Quantification of VNA titers by antigen-specific ELISA at various times, following a single intravenous injection of 2 µg of mRNA-LNP encoding either VNA-BoNTA or VNA-Stx2. For each time point a different cohort of mice was used.

Data information: Individual measurements as well as means are given for each time point.



Appendix Figure S8. Correlation of IgG titers and ADA responses.

All animals used for analysis of antibody expression kinetics (Fig. 3C) were bled on day 28 and antibody titers were determined using an IgG specific ELISA. ADA titers were determined by an ADA ELISA that specifically detects humoral responses against the anti-rabies antibody using day -5 (pre-bleed) and day 28 samples. Correlation of antibody and ADA titers was determined by two-tailed spearman correlation analysis.

Data information: Bars represent individual measurements.



Appendix Figure S9. Histopathological analysis of liver sections after mRNA-LNP treatment.

- A, B C, D Histopathological analysis of liver sections of untreated mice at high (A) and low (B) magnification. Histopathological analysis of liver sections of mice after mRNA-LNP treatment at high (C)
 - and low (D) magnification.



Appendix Figure S10. Protection of mice against BoNT/A challenge by mRNA-LNP administered at various times post intoxication.

A, B
 CD1 mice received a single intravenous injection of 2 µg of recombinant VNA-BoNTA or 40 µg of mRNA-LNP encoding either VNA-BoNTA or VNA-Stx2 at two (A) or four (B) hours after a lethal 4x LD50 intravenous BoNT/A challenge. Survival was monitored for six days. A total of ten mice per group were challenged.

Analysis of cytokine induction following mRNA-LNP administration

mRNA-LNP dose		40 µg (2	2 mg/kg)	
Cytokine (pg/ml)	TNF	IL-6	GM-CSF	IL-12p70
Day -5	2,8 ± 1	1,9 ± 1	3,1 ± 6,1	Not detected
6 hours	80,9 ± 19,8	298,8 ± 92,1	8,9 ± 6,1	Not detected

Supporting information Fig. 4b



early sign of rabies encephalitis: ruffled fur, excessive grooming, restless / overly active, coordination problems (unsteady gait), blinking/squeezing of eyes, arched back progression to rabies encephalitis: ruffled fur, impaired use of one of the hind legs, inflexible tail, hunchback

rabies encephalitis (humane endpoint): impaired use of the hind quarter, rolls over when walking, inability to stand up, hunchback, inflexible tail / curled upwards



< 80 % of Day 0 Humane endpoint was also reached if the weight of mice reduced more than 5 % on two following days.

												Day	after	Chall	enge)								
	Mouse	Parameter	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
	#1	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	π 1	BW	100	100	108	108	108	106	105	107	112	114	112	111	113	114	116	118	120	119	121	122	120	119
	#2	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#2	BW	100	101	109	111	108	108	109	107	112	111	111	114	114	114	114	116	117	119	118	117	123	121
	#3	Score	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Anti-rabies (40ug)		BW	100	101	108	108	109	107	108	110	115	114	113	116	115	115	116	118	117	116	119	120	116	113
Day -1	#4	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		BW	100	102	109	107	106	107	107	104	106	108	108	109	109	109	110	112	110	106	106	110	110	109
	#5	Score	0	0	0	1	0	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1
		BW	100	101	110	104	101	101	98	97	104	104	101	104	104	108	107	107	108	107	107	109	113	113
	#6	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		BW	100	102	112	112	108	107	109	108	112	110	109	112	114	113	114	115	119	118	119	115	116	114
r			1 -	-	-	-	-	-	_	-						•	<u> </u>	•	N	<u> </u>	<u> </u>	N		
	#1	Score	0	0	0	0	0	0	0	0	1	3	NA	NA	MA	MA	MA	MA	MA	MA	MA	MA	MA	MA
		BW	100	99	105	109	109	107	108	100	94	87	\leftarrow	\leftrightarrow	\leftrightarrow	\leftarrow	\leftarrow	\leftarrow	\leftrightarrow	\leftrightarrow	\leftarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	#2	Score	0	0	0	0	0	0	1	3	NA	NA	N/A	NA	NA	NA	N/A	NA	NA	NA	NA	NA	NA	NA
		BW	100	100	106	108	109	108	99	91	\leftrightarrow	\leftarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow						
	#3	Score	100	0	0	0	0	1	2	3	Ì∭A	NA	N∕A	N∕A	NA	N∕A	N ∧ A	N ∧ A	N∕A	Ŋv∕A	N∕A	N∕A	NKA	NA
Anti-Influenza B (40ug)		BW	100	101	107	112	109	98	90	81	$ \simeq$	\sim		\sim	\sim			$\frac{1}{2}$	\sim	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
Day -1	#4	Score	100	102	104	110	111	111	100	110	100	111	1	02	0	0	1	2	2	Ì∭A	NKA	NA	ÌMA	NA
		Score	100	102	0	0	0	1	2	2	109		90	92	69	65	, 9 \	(³)	07	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	#5	BW	100	0	106	107	106	05	2	- 3 - 70	Ì¥.	NA	N∕A	N∕A	NA	N∕A	Ì∳ (À	N∕A	N∕A	ÌM∕A	NKA	N∕A	ÌMA	NA
		Score	001	90	0	0	0	90 1	00	2	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftarrow	\leftarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow
	#6	BW	100	100	104	107	108	107	91	85	\mathbb{M}	Ì₩A	×	X	Ì₩A	×	×	M M A	×	Ì₩A	×	×	×	Ì₩A

Supporting information Fig. 4d



early sign of rabies encephalitis: ruffled fur, excessive grooming, restless / overly active, coordination problems (unsteady gait), blinking/squeezing of eyes, arched back progression to rabies encephalitis: ruffled fur, impaired use of one of the hind legs, inflexible tail, hunchback

rabies encephalitis (humane endpoint): impaired use of the hind quarter, rolls over when walking, inability to stand up, hunchback, inflexible tail / curled upwards



< 80 % of Day 0 Humane endpoint was also reached if the weight of mice reduced more than 5 % on two following days.

												Day	after	Chall	lenge	•								
	Mouse	Parameter	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
	#1	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#1	BW	100	93	93	98	101	102	104	101	107	106	107	109	109	110	111	112	112	115	115	115	120	117
	#2	Score	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	1	1	1	0	0	1	1
	#2	BW	100	95	96	103	100	100	97	91	92	100	101	106	102	108	106	104	102	103	102	103	104	104
	#2	Score	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Anti-rabies (40ug)	#3	BW	100	94	94	99	99	99	100	100	105	105	105	106	104	107	104	107	108	111	109	110	111	111
+2 hours	#4	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#4	BW	100	96	100	104	106	104	106	101	103	103	101	102	101	104	102	102	101	103	103	104	105	106
	#5	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#5	BW	100	95	96	99	101	98	98	100	102	102	103	103	103	103	102	105	104	105	108	108	111	111
	#6	Score	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#0	BW	100	94	96	100	97	96	97	96	101	99	99	102	100	102	100	102	101	103	107	105	107	105
	#1	Score	0	0	0	0	0	2	3															
	π ι	BW 100	97	98	103	103	94	87		22			$\sim \sim$	\mathcal{N}	25	25	25	22	22	22	22	25	22	
	#2	Score	0	0	0	0	0	1	2	2	2													
Anti-influenza B (40ug) +2 hours	#2	BW	100	93	96	100	96	93	84	76	71	\sim	25	27	25	22	22	22	25	22	22	22	22	2
	#2	Score	0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	1	1	1	1	1	1
	#3	BW	100	90	91	97	100	100	101	101	105	100	90	86	85	86	85	84	85	84	85	93	91	93
	#4	Score	0	0	0	0	0	1	3															
	#4	BW	100	94	94	100	100	88	82	25	22	25	25	22	25	25	22	25	22	22	22	22	25	22
	#5	Score	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#5	BW	100	96	95	100	101	100	99	98	101	101	1 99 99	98	97	100	100	102	101	103	104	102	102	
	#6	Score	0	0	0	0	0	1	2	3	\searrow		\mathbb{N}	\mathbb{N}	\searrow	\mathbb{N}	\mathbb{N}	\mathbb{N}	\mathbb{N}	\searrow	\searrow			
	#0	BW	100	95	97	100	101	95	89	83	124	124	124	124	124	124		124	124		174			

Supporting information Fig. 4e



early sign of rabies encephalitis: ruffled fur, excessive grooming, restless / overly active, coordination problems (unsteady gait), blinking/squeezing of eyes, arched back progression to rabies encephalitis: ruffled fur, impaired use of one of the hind legs, inflexible tail, hunchback

rabies encephalitis (humane endpoint): impaired use of the hind quarter, rolls over when walking, inability to stand up, hunchback, inflexible tail / curled upwards



< 80 % of Day 0 Humane endpoint was also reached if the weight of mice reduced more than 5 % on two following days.

												Day	after	Chal	lenge									
	Mouse	Parameter	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
	#1	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#1	BW	100	96	96	95	95	95	95	95	95	97	94	95	96	97	97	100	100	99	97	96	97	98
	#2	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#2	BW	100	95	94	99	97	96	94	95	95	98	99	100	100	103	105	109	110	107	103	102	104	107
	#3	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#3	BW	100	96	97	101	102	99	99	98	97	100	98	98	100	98	98	100	102	104	103	105	106	105
	#4	Score	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	0	0	0	0	0	0
Anti-rabies	π 4	BW	100	96	101	104	104	97	96	96	95	99	96	96	99	99	102	100	102	103	102	104	106	106
(40 µg mRNA-LNP)	#5	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#3	BW	100	88	89	94	97	99	99	99	98	103	104	101	104	106	109	110	109	111	107	105	106	99
	#6	Score	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	2	2	1	1	1	1	1
	#0	BW	100	98	101	102	95	93	90	90	89	87	88	89	90	95	95	93	95	97	95	96	100	98
	#7	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	#1	BW	100	93	96	97	93	95	88	89	90	91	92	89	89	91	93	93	96	96	95	99	100	97
	#8	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		BW	100	96	98	100	101	102	101	103	102	101	102	102	103	105	107	104	106	106	108	112	112	109
			_																					
	#1	Score	0	0	0	0	0	0	3		M	M	$\mathbb{N}_{\mathbb{A}}$	\mathbf{N}	MA			M		N/A	M			MA
		BW	100	93	91	97	99	88	82	ŻŇ	ŻŃ	ŻŃ	ĮΖ\		ŻŇ	ŻŇ	ŻŇ	ŻŃ	ŻŃ	ZŇ	ŻŇ	Σ	ŻŃ	ZŇ
	#2	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	=	BW	100	98	97	98	98	96	98	99	98	98	96	97	98	96	95	93	92	98	99	99	100	99
	#3	Score	0	0	0	0	0	0	2	3		M	M	\mathbb{N}				MA		MA			M	NA
		BW	100	95	98	102	102	93	89	82	ŻŇ	ŻŃ	27	<u>i X</u>	ŻŃ	ŻŇ	ŻŇ	ŻŇ	ŻŇ	ŻŚ	ŻŇ	ŻŇ	ZΥ	ĽΥ
	#4	Score	0	0	0	0	0	0	1	1	2	MA			NA	NA		NA	MA	MA	NA	NA	MA	NA
Anti-influenza B		BW	100	92	92	96	96	96	89	80	72	\sum			Σ	\sim	\sum	Σ	Σ	Δ	Σ	\sim	ΖŇ	Δ
(40 μg mRNA-LNP)	#5	Score	0	0	0	0	0	0	2	3	MA	MA	MA		MA	MA		MA		MA	MA	NA	MA	NA
		BW	100	96	97	97	98	92	86	80	\sum	\sum			Σ	\sum	Σ	Σ	Σ	Δ	Σ	\sim	ΖŇ	\sum
	#6	Score	0	0	0	0	0	1	2	NA		NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		BW	100	93	93	92	95	87	81	ŻŇ	<u> </u>	<u> </u>			<u> </u>	\simeq	Σ	<u> </u>	\simeq	Â	Z'	Å	Â	Ž
	#7	Score	0	0	0	0	0	0	2	3	NA	NA	NA		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		BW	100	93	93	94	94	88	81	76	Δ	\sim			\bigtriangleup	Δ	\sim	\square	\bigtriangleup	Δ	\bigtriangleup	\bigtriangleup	\bigtriangleup	\bigtriangleup
	#8	Score	0	0	0	0	0	0	2	3	NA	NA					NA	NA		NA		NA	NA	NA
		BW	100	94	91	92	91	82	78	74	X	1X	1XX	17X	X	X	X	121	X	X	X	\sum	X	X

Appendix Table S4 continued

Supporting information Fig. 4e



no clinical signs early sign of rabies encephalitis: ruffled fur, excessive grooming, restless / overly active, coordination problems (unsteady gait), blinking/squeezing of eyes, arched back progression to rabies encephalitis: ruffled fur, impaired use of one of the hind legs, inflexible tail, hunchback

rabies encephalitis (humane endpoint): impaired use of the hind quarter, rolls over when walking, inability to stand up, hunchback, inflexible tail / curled upwards

Body Weight (BW)
< 90 % of Day 0
< 85 % of Day 0
< 80 % of Day 0

Humane endpoint was also reached if the weight of mice reduced more than 5 % on two following days.

Mouse Parameter 0 1 2 3 4 5 6 7 8 9 10 11 21 13 14 15 15 17 18 19 10 0 <th></th> <th>Day</th> <th>after</th> <th>Chall</th> <th>enge</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>													Day	after	Chall	enge										
41 Score 0 <th></th> <th>Mouse</th> <th>Parameter</th> <th>0</th> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> <th>6</th> <th>7</th> <th>8</th> <th>9</th> <th>10</th> <th>11</th> <th>12</th> <th>13</th> <th>14</th> <th>15</th> <th>16</th> <th>17</th> <th>18</th> <th>19</th> <th>20</th> <th>21</th>		Mouse	Parameter	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
Anti-rables (10 µg LM+mRNA) 11 Score 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		#1	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
#2 Score 0 <th></th> <th></th> <th>BW</th> <th>100</th> <th>97</th> <th>99</th> <th>100</th> <th>100</th> <th>98</th> <th>100</th> <th>100</th> <th>99</th> <th>100</th> <th>99</th> <th>103</th> <th>102</th> <th>101</th> <th>103</th> <th>105</th> <th>103</th> <th>105</th> <th>107</th> <th>106</th> <th>109</th> <th>107</th>			BW	100	97	99	100	100	98	100	100	99	100	99	103	102	101	103	105	103	105	107	106	109	107	
Anti-rables (10 µg LNP-mRNA) H Score 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		#2	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Anti-rabies (10 µg LNP-mRNA) 46 5 5 5 5 5 5 5 5 5		\vdash	BW	94	94	95	95	95	94	94	97	96	97	97	100	100	100	99	97	96	97	98	97	99	100	
Anti-rables (10 µg LNP-mRNA) 44 5 5 5 5 6 6 5 5 6 5 5		#3	Score	0	0	102	0	0	0	2	3	X	M∕.	M	M	M	M	MA	MA	MA	M	M	N ∧ ∧	MA	X	
Anti-tables (10 µg LNP-mRNA) #6 BW 10 µg LNP-mRNA) #7 BW 10 µg LNP-mRNA) #6 BW 10 µg LNP-mRNA) #7 BW 10 µg LNP-mRNA) #1 Anti-influenza B (10 µg LNP-mRNA) #1 Score 10 µg LNP-mRNA) #2 Score 10 µg LNP-MRNA)			Score	101	100	102	95	94	00	03	/6	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	\sim	
10 μg LNP-mRNA) 15 10 μg	Anti-rahies	#4	BW	96	03	100	100	aa	03	95	98	97	95	03	95	96	94	97	aa	aa	100	aa	100	97	95	
#5 BW 101 101 100 99 66 11 16 190 0	(10 ug LNP-mRNA)		Score	0	0	0	0	0	1	3	3		Ň	Ň	Ň	Ň	<u> </u>	Š/	Ň.	ŇŽ		Ň	$\overline{\mathbf{N}}$	Š7	Š.	
f6 Score 0 <th>(</th> <th>#5</th> <th>BW</th> <th>101</th> <th>101</th> <th>100</th> <th>99</th> <th>96</th> <th>91</th> <th>85</th> <th>76</th> <th>×</th> <th>X</th> <th>X</th> <th>X</th> <th>X</th> <th>X</th> <th>×</th> <th>X</th> <th>X</th> <th>X</th> <th>X</th> <th>X</th> <th>×</th> <th>\aleph</th>	(#5	BW	101	101	100	99	96	91	85	76	×	X	X	X	X	X	×	X	X	X	X	X	×	\aleph	
Ho BW 100 97 100 101 102 101 102 103 102 103 102 103			Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
87 Score 0 0 0 0 2 3 0 <th>#6</th> <th>#b</th> <th>BW</th> <th>100</th> <th>97</th> <th>100</th> <th>101</th> <th>102</th> <th>101</th> <th>102</th> <th>103</th> <th>102</th> <th>102</th> <th>101</th> <th>100</th> <th>102</th> <th>103</th> <th>102</th> <th>104</th> <th>104</th> <th>104</th> <th>102</th> <th>104</th> <th>104</th> <th>103</th>	#6	#b	BW	100	97	100	101	102	101	102	103	102	102	101	100	102	103	102	104	104	104	102	104	104	103	
BW 99 96 96 99 91 94 0<		#7	Score	0	0	0	0	0	2	3																
#8 Score BW 0		#1	BW	99	96	96	99	98	91	84	\sim	2	2	2	2	2	\sim	27	2	2	25		2	2	\sim	
BW 101 96 99 100 103 103 104 103 104 104 104 105 105 104 105 105 104 105 105 104 105 105 104 105 105 104 105 104 105 105 104 104 105 105 104 104 104 105 105 104 104 104 104 105 105 104 104 104 105 104 104 104 105 104 104 104 105 104 105 104 104 105 104 105 104 104 105 104 105 104 104 105 104 105 104 104 105 104 105 104 105 104 105 104 104 105 104 104 105 104 104 105 104 104 105 104		#8	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
#1 Score 0 0 0 1 3 #2 Score 0 <td< th=""><th></th><th></th><th>BW</th><th>101</th><th>96</th><th>99</th><th>100</th><th>103</th><th>102</th><th>103</th><th>103</th><th>104</th><th>103</th><th>103</th><th>101</th><th>103</th><th>104</th><th>104</th><th>105</th><th>105</th><th>105</th><th>104</th><th>105</th><th>104</th><th>104</th></td<>			BW	101	96	99	100	103	102	103	103	104	103	103	101	103	104	104	105	105	105	104	105	104	104	
#1 Score 0 0 0 0 1 1 0 0 1 0 <th></th> <th><u> </u></th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>4</th> <th>2</th> <th></th> <th><u>^</u></th> <th></th> <th></th>		<u> </u>	0	0	0	0	0	0	4	2													<u>^</u>			
Anti-influenza B (10 µg LNP-mRNA) BW 100 00 0		#1	Score	100	100	100	102	102	08	3	Ì₩A	N €	MA	₩.	M €	N N A	X	Ì₩A	Ì₩.	MA	Ì∭ (Å	M	M €	Ì₩.	\mathbf{M}	
#1 BW 100 86 91 13 72 73 74 74 74 74 75 75 76 <t< th=""><th></th><th></th><th>Score</th><th>100</th><th>100</th><th>100</th><th>0</th><th>103</th><th>90</th><th>93</th><th>\leftrightarrow</th><th>\leftrightarrow</th><th>\longleftrightarrow</th><th>\leftrightarrow</th><th>\leftrightarrow</th><th>\longleftrightarrow</th><th>\leftrightarrow</th><th>\leftrightarrow</th><th>\leftrightarrow</th><th>\longleftrightarrow</th><th>\leftrightarrow</th><th>\leftarrow</th><th>\longleftrightarrow</th><th>\leftrightarrow</th><th>\leftrightarrow</th></t<>			Score	100	100	100	0	103	90	93	\leftrightarrow	\leftrightarrow	$ \longleftrightarrow $	\leftrightarrow	\leftrightarrow	$ \longleftrightarrow $	\leftrightarrow	\leftrightarrow	\leftrightarrow	$ \longleftrightarrow $	\leftrightarrow	\leftarrow	$ \longleftrightarrow $	\leftrightarrow	\leftrightarrow	
Anti-influenza B (10 µg LNP-mRNA) Score #3 Score BW 100 0 0 Score 0 0 0 0		#2	BW	100	96	94	96	94	85	78	×	×	×	×	×	X	×	×	×	×	×	×	X	×	\aleph	
Anti-influenza B (10 µg LNP-mRNA) #4 Score 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	$\left(1 \right)$	
Anti-influenza B (10 µg LNP-mRNA) #4 Score 0 0 0 0 1 3 0 0 0 0 0 0 0 0 0 1 3 0 0 0 0 0 0 0 0 0 1 2 3 0		#3	BW	100	95	97	99	98	95	95	95	94	94	95	87	88	90	86	85	86	90	94	95	95	97	
Anti-influenza B (10 µg LNP-mRNA) Image: https://www.marked.points/image: https://www.marked		#4	Score	0	0	0	0	0	1	3			\searrow											\searrow	\searrow	
(10 µg LNP-mRNA) #5 Score 0 0 0 0 1 2 3 N	Anti-influenza B	#4	BW	100	98	101	104	103	89	84															X	
H BW 100 96 97 86 81 73 73 74 75<	(10 µg LNP-mRNA)	#5	Score	0	0	0	0	0	1	2	3															
#6 Score 0 <th></th> <th></th> <th>BW</th> <th>100</th> <th>96</th> <th>99</th> <th>98</th> <th>97</th> <th>86</th> <th>81</th> <th>73</th> <th>27</th> <th>ΓĽ Υ</th> <th>23</th> <th>2</th> <th><u>ک</u>ک</th> <th>Ň</th> <th>\sim</th> <th>Ń</th> <th>ΓĽ.</th> <th>\sim</th> <th>\sum</th> <th>ľ</th> <th>Ň</th> <th>\sim</th>			BW	100	96	99	98	97	86	81	73	27	ΓĽ Υ	23	2	<u>ک</u> ک	Ň	\sim	Ń	ΓĽ.	\sim	\sum	ľ	Ň	\sim	
BW 100 97 100		#6	Score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
#7 Score 0 0 0 0 2 3 100 103 102 102 103 103 102 103 103 102 103			BW	100	97	100	102	101	100	99	95	96	97	96	95	97	95	99	101	101	100	101	100	101	102	
BW HOU HOU <th></th> <th>#7</th> <th>Score</th> <th>100</th> <th>100</th> <th>102</th> <th>102</th> <th>102</th> <th>05</th> <th>2</th> <th>3</th> <th>Ì∭A</th> <th>N∕A</th> <th>N∕A</th> <th>MA </th> <th>N∕A</th> <th>M</th> <th>MA</th> <th>ÌM∕A</th> <th>N∕A</th> <th>N∕A</th> <th>Ì.∭A</th> <th>MA</th> <th>ÌM∕A</th> <th>\mathbf{M}</th>		#7	Score	100	100	102	102	102	05	2	3	Ì∭A	N∕A	N∕A	MA	N∕A	M	MA	ÌM∕A	N∕A	N∕A	Ì.∭A	MA	ÌM∕A	\mathbf{M}	
#8 Score 0 1 3 0 0 0 0 0 0 1 3 0 0 0 0 0 0 0 0 1 3 0 <th></th> <th>\vdash</th> <th>Score</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>102</th> <th>95</th> <th>00</th> <th>00</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>$\overline{1}$</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th> <th>\sim</th>		\vdash	Score	0	0	0	0	102	95	00	00	\sim	\sim	\sim	\sim	\sim	\sim	$\overline{1}$	\sim	\sim	\sim	\sim	\sim	\sim	\sim	
PBS #1 Score 0 0 0 1 3 0 0 1 0 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0		#8	BW	100	101	101	99	96	97	99	97	97	94	92	92	96	95	98	100	103	103	102	102	103	106	
#1 Score 0 0 0 1 3 0 0 0 1 3 #2 BW 100 98 96 94 83 78 0					1.01	1.01			ο.	00	0.	0.		02	02			00				102	1.02			
#1 BW 100 98 96 94 83 78 <t< th=""><th></th><th>#4</th><th>Score</th><th>0</th><th>0</th><th>0</th><th>0</th><th>0</th><th>1</th><th>3</th><th></th><th></th><th>\mathbb{N}</th><th>\mathbb{N}</th><th>\mathbb{N}</th><th>\mathbb{N}</th><th>\mathbb{N}</th><th></th><th>\searrow</th><th>\mathbb{N}</th><th></th><th></th><th>\mathbb{N}</th><th></th><th>\searrow</th></t<>		#4	Score	0	0	0	0	0	1	3			\mathbb{N}	\mathbb{N}	\mathbb{N}	\mathbb{N}	\mathbb{N}		\searrow	\mathbb{N}			\mathbb{N}		\searrow	
#2 Score 0 0 0 2 3 0 0 0 0 0 0 0 0 2 3 0 <th></th> <th>#1</th> <th>BW</th> <th>100</th> <th>98</th> <th>96</th> <th>96</th> <th>94</th> <th>83</th> <th>78</th> <th>X</th> <th></th> <th>1XCA</th> <th>1XA</th> <th>1XA</th> <th></th> <th>1XA</th> <th>1XA</th> <th>1XA</th> <th>1XA</th> <th></th> <th></th> <th>IXA</th> <th>1XA</th> <th></th>		#1	BW	100	98	96	96	94	83	78	X		1XCA	1XA	1XA		1XA	1XA	1XA	1XA			IXA	1XA		
PBS		#2	Score	0	0	0	0	0	2	3																
#3 Score 0 0 0 0 1 13 BW 100 97 96 97 98 90 85 79 90 90 85 79 90 90 85 79 90 90 85 79 90 90 85 79 90 90 90 85 79 90 <th></th> <th></th> <th>BW</th> <th>100</th> <th>102</th> <th>101</th> <th>99</th> <th>100</th> <th>87</th> <th>80</th> <th><i>Z</i></th> <th>ζ^ζ</th> <th>ß</th> <th>ß</th> <th>ß</th> <th>ß</th> <th>ß</th> <th>\sim</th> <th>ß</th> <th>ß</th> <th>ß</th> <th></th> <th>ß</th> <th>ß</th> <th>\sim</th>			BW	100	102	101	99	100	87	80	<i>Z</i>	ζ ^ζ	ß	ß	ß	ß	ß	\sim	ß	ß	ß		ß	ß	\sim	
BW 100 97 96 97 98 90 85 79 79 70 <th 70<="" th=""><th></th><th>#3</th><th>Score</th><th>0</th><th>0</th><th>0</th><th>0</th><th>0</th><th>0</th><th>1</th><th>3</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>NA</th><th>MA</th><th>NA</th><th>NA</th></th>	<th></th> <th>#3</th> <th>Score</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>0</th> <th>1</th> <th>3</th> <th>NA</th> <th>MA</th> <th>NA</th> <th>NA</th>		#3	Score	0	0	0	0	0	0	1	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	MA	NA	NA
#4 Score 0 0 0 0 3 <th></th> <th></th> <th>BW</th> <th>100</th> <th>97</th> <th>96</th> <th>97</th> <th>98</th> <th>90</th> <th>85</th> <th>79</th> <th>$\langle \cdot \rangle$</th> <th>\leftrightarrow</th> <th>$\langle \cdot \rangle$</th> <th>$\langle \cdot \rangle$</th> <th>$\langle \cdot \rangle$</th> <th>$\langle \cdot \rangle$</th> <th></th> <th>\leftrightarrow</th> <th>\leftrightarrow</th>			BW	100	97	96	97	98	90	85	79	$\langle \cdot \rangle$	\leftrightarrow	$\langle \cdot \rangle$	$\langle \cdot \rangle$	$\langle \cdot \rangle$	$\langle \cdot \rangle$		\leftrightarrow	\leftrightarrow						
BV 100 101 102 103 103 104 103 103 104		#4	Score	100	101	102	102	02	3	N∕A	NA	Ì∭A	N∕A	N∕A	M	N∕A	MA	M	ÌM∕A	NA	N∕A	N∕A	NA €	M	\mathbf{M}	
#5 3cure 0 0 0 1 1 2 2 3 <th>PBS</th> <th>\vdash</th> <th>BW Score</th> <th>0</th> <th>101</th> <th>102</th> <th>103</th> <th>93</th> <th>04</th> <th>$\langle \rangle$</th> <th>\leftrightarrow</th> <th>\leftarrow</th> <th>\longleftrightarrow</th> <th>\leftrightarrow</th> <th>\leftrightarrow</th>	PBS	\vdash	BW Score	0	101	102	103	93	04	$\langle \rangle$	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftarrow	$ \longleftrightarrow $	\leftrightarrow	\leftrightarrow	
BW 100	#5	#5	BW	100	100	101	103	100	02	3	X	X	₩.	X	X	M €	X	×	X	₩.	X	I ∭A	M M A	Ì∭A	×	
#6 BW 100 97 96 98 97 79 X			Score	0	0	0	0	0	1	3	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	✐	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\longleftrightarrow	✐	\leftrightarrow	\leftrightarrow	\leftrightarrow	
#7 Score 0 0 0 1 2 2 #8 BW 100 101 101 99 100 90 83 76 7		#6	BW	100	97	96	98	98	87	79	×	×	X	X	X	X	×	×	X	X	×	×	X	×	\aleph	
#/ BW 100 101 101 99 83 76 <th7< th=""><th colspan="2"></th><th>Score</th><th>0</th><th>0</th><th>0</th><th>0</th><th>0</th><th>1</th><th>2</th><th>2</th><th>$\langle \rangle$</th><th>⇇∕</th><th></th><th>\bigstar</th><th>⇇之</th><th>\longleftrightarrow</th><th></th><th></th><th>⇇之</th><th></th><th>ĸŻ</th><th>\bigstar</th><th>\longleftrightarrow</th><th>\overleftrightarrow</th></th7<>			Score	0	0	0	0	0	1	2	2	$\langle \rangle$	⇇∕		\bigstar	⇇之	\longleftrightarrow			⇇之		ĸŻ	\bigstar	\longleftrightarrow	\overleftrightarrow	
#8 Score 0 0 0 0 3 BW 100 93 92 92 87 79		#7	BW	100	101	101	99	100	90	83	76	X	X	X	X	X	X	X	X	X	X	X	X	X	\mathbb{X}	
BW 100 93 92 92 87 79 X X X X X X X X X X		#0	Score	0	0	0	0	0	3				\searrow	\searrow	$\mathbf{\nabla}$	$\mathbf{\nabla}$	\searrow	$\mathbf{\nabla}$	\searrow	\searrow			\searrow	\searrow	\searrow	
		#8	BW	100	93	92	92	87	79	1XA	X	1XA	1XA	X	X	, IXA	X	1XA	X	1XA	1XA	1XA	J∕XA	1XA	1XA	